PL3018208T3 - Ulepszona struktura oligonukleotydowa typu nanocząstki o wysokiej wydajności i sposób jej wytwarzania - Google Patents

Ulepszona struktura oligonukleotydowa typu nanocząstki o wysokiej wydajności i sposób jej wytwarzania

Info

Publication number
PL3018208T3
PL3018208T3 PL14819529T PL14819529T PL3018208T3 PL 3018208 T3 PL3018208 T3 PL 3018208T3 PL 14819529 T PL14819529 T PL 14819529T PL 14819529 T PL14819529 T PL 14819529T PL 3018208 T3 PL3018208 T3 PL 3018208T3
Authority
PL
Poland
Prior art keywords
high efficiency
preparing same
oligonucleotide structure
type oligonucleotide
nanoparticle type
Prior art date
Application number
PL14819529T
Other languages
English (en)
Inventor
Han Oh Park
Jeiwook CHAE
Pyoung Oh Yoon
Boram HAN
Gi-Eun CHOI
Youngho KO
Taewoo Kwon
Jae Don Lee
Sun Gi Kim
Original Assignee
Bioneer Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioneer Corporation filed Critical Bioneer Corporation
Publication of PL3018208T3 publication Critical patent/PL3018208T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL14819529T 2013-07-05 2014-07-04 Ulepszona struktura oligonukleotydowa typu nanocząstki o wysokiej wydajności i sposób jej wytwarzania PL3018208T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130079309 2013-07-05
PCT/KR2014/006031 WO2015002511A1 (ko) 2013-07-05 2014-07-04 개선된 고효율 나노입자형 올리고뉴클레오타이드 구조체 및 그의 제조방법
EP14819529.0A EP3018208B1 (en) 2013-07-05 2014-07-04 Improved nanoparticle type oligonucleotide structure having high efficiency and method for preparing same

Publications (1)

Publication Number Publication Date
PL3018208T3 true PL3018208T3 (pl) 2020-09-21

Family

ID=52144016

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14819529T PL3018208T3 (pl) 2013-07-05 2014-07-04 Ulepszona struktura oligonukleotydowa typu nanocząstki o wysokiej wydajności i sposób jej wytwarzania

Country Status (13)

Country Link
US (1) US10030243B2 (pl)
EP (1) EP3018208B1 (pl)
JP (1) JP6422961B2 (pl)
KR (1) KR101862349B1 (pl)
CN (1) CN105705638B (pl)
AU (1) AU2014284834B2 (pl)
BR (1) BR112016000160B1 (pl)
CA (1) CA2917299C (pl)
ES (1) ES2809481T3 (pl)
MX (1) MX378462B (pl)
PL (1) PL3018208T3 (pl)
RU (1) RU2670164C2 (pl)
WO (1) WO2015002511A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD800848S1 (en) 2016-03-24 2017-10-24 Judy Janke Male doll
USD800850S1 (en) 2016-03-24 2017-10-24 Judy Janke Female doll
KR101861738B1 (ko) * 2016-08-24 2018-05-29 (주)바이오니아 마이크로 rna를 포함하는 이중나선 올리고 rna 구조체
AU2018209934B2 (en) * 2017-01-18 2023-11-09 Alnylam Pharmaceuticals, Inc. Endosomal cleavable linkers
KR102473989B1 (ko) * 2018-11-28 2022-12-07 (주)바이오니아 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물
US20220088051A1 (en) * 2019-01-15 2022-03-24 Bioneer Corporation Double-stranded oligonucleotide targeting dkk1 gene, construct including same, and hair loss prevention or hair growth composition containing same
KR102376945B1 (ko) * 2019-12-19 2022-03-21 상지대학교산학협력단 파킨슨병용 약제학적 조성물 및 그 치료제
EP3896161A1 (en) * 2020-04-17 2021-10-20 Bia Separations D.O.O. A method of single-stranded rna purification
EP3896160B1 (en) * 2020-04-17 2025-06-04 Sartorius BIA Separations d.o.o. A method of single-stranded rna purification
JP2023545420A (ja) * 2020-10-12 2023-10-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 高分子を細胞に送達するためのエンドソームエスケープドメイン
CN116568334A (zh) * 2020-10-12 2023-08-08 加利福尼亚大学董事会 用于将大分子递送至细胞中的内体逃逸结构域
US20240299437A1 (en) * 2021-02-25 2024-09-12 Bioneer Corporation Composition for alleviating hair graying, promoting hair growth and/or preventing or alleviating hair loss, comprising double-stranded mirna as active ingredient
JP2024509906A (ja) 2021-03-08 2024-03-05 バイオニア コーポレーション Ｃｏｖｉｄ‐１９を含む呼吸器系ウイルス感染症、ウイルス感染を原因とする肺線維症、又は呼吸器疾患の予防又は治療のために超音波ネブライザを使用して二本鎖オリゴヌクレオチド構造物を投与するための組成物
WO2024206870A1 (en) * 2023-03-29 2024-10-03 Sir Nagen Therapeutics Incorporated Dna-rna heteroduplex targeting androgen receptor

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5386023A (en) 1990-07-27 1995-01-31 Isis Pharmaceuticals Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling
CA2159626C (en) 1993-04-02 2001-10-02 Lingna Li Method for delivering beneficial compositions to hair follicles
US6277967B1 (en) 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6175001B1 (en) 1998-10-16 2001-01-16 The Scripps Research Institute Functionalized pyrimidine nucleosides and nucleotides and DNA's incorporating same
US20030224353A1 (en) 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
CA2576925C (en) 2004-08-16 2013-12-10 The Cbr Institute For Biomedical Research, Inc. Method of delivering rna interference and uses thereof
WO2006039369A1 (en) 2004-09-29 2006-04-13 Alza Corporation Microparticles and nanoparticles containing a lipopolymer
TWI386225B (zh) 2004-12-23 2013-02-21 Alcon Inc 用於治療眼睛病症的結締組織生長因子（ＣＴＧＦ）ＲＮＡ干擾（ＲＮＡｉ）抑制技術
CA2619533C (en) 2005-08-17 2014-02-04 Bioneer Corporation Sirna-hydrophilic polymer conjugates for intracellular delivery of sirna and method thereof
WO2007044468A2 (en) 2005-10-05 2007-04-19 The Cbr Institute For Biomedical Research, Inc. Method to treat flavivirus infection with sirna
WO2007084797A1 (en) 2006-01-23 2007-07-26 Abbott Laboratories Chemically modified polycation polymer for sirna delivery
BRPI0715821A2 (pt) 2006-08-24 2013-07-23 Alcon Res Ltd inibiÇço de gremlina mediada por rnai para tratamento de condiÇÕes relacionadas À iop
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US8067473B2 (en) 2007-01-16 2011-11-29 Teva Pharmaceutical Industries, Ltd. Methods for enhancing the therapeutic efficacy of topoisomerase inhibitors
EP2205740A2 (en) * 2007-10-02 2010-07-14 Rxi Pharmaceuticals Corp. Tripartite rnai constructs
CA2910760C (en) * 2007-12-04 2019-07-09 Muthiah Manoharan Targeting lipids
AU2009302217A1 (en) 2008-10-09 2010-04-15 Northeastern University Multifunctional self-assembling polymeric nanosystems
KR101800833B1 (ko) 2009-03-20 2017-11-23 씨엘에스엔 래버러토리스, 인코퍼레이티드 폴리아민 유도체
KR101224828B1 (ko) 2009-05-14 2013-01-22 (주)바이오니아 ｓｉＲＮＡ 접합체 및 그 제조방법
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
AR078921A1 (es) 2009-11-09 2011-12-14 Hoffmann La Roche Composiciones y metodos para inhibir la expresion de genes de la superfamilia de quinesinas, kif10
US20110206617A1 (en) 2010-02-22 2011-08-25 Krishnendu Roy Modified polysaccharides for drug and contrast agent delivery
RU2466188C2 (ru) * 2010-11-08 2012-11-10 Российская Федерация, от имени которой выступает Министерство образования и науки Ингибитор репродукции вируса гриппа а на основе комплекса наночастиц диоксида титана и олигонуклеотида
US9328347B2 (en) 2011-07-18 2016-05-03 Oregon Health & Science University siRNA useful in the treatment of flavivirus infection
ES2954991T3 (es) 2011-07-29 2023-11-28 Karyopharm Therapeutics Inc Moduladores del transporte nuclear que contienen hidrazida y usos de los mismos
US10023861B2 (en) * 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
ES2897565T3 (es) 2011-10-18 2022-03-01 Dicerna Pharmaceuticals Inc Lípidos catiónicos de amina y uso de los mismos
BR112014014730B1 (pt) * 2011-12-15 2021-05-18 Bioneer Corporation estrutura de droga polímero terapêutica, métodos para preparar uma estrutura de oligo rna de dupla hélice, nanoparticula e composição farmacêutica
KR20130068032A (ko) 2011-12-15 2013-06-25 (주)바이오니아 안정한 안티센스 올리고뉴클레오티드 접합체 및 그 제조방법
AU2013206989B2 (en) 2012-01-05 2015-05-28 Bioneer Corporation High-efficiency nanoparticle-type double-helical oligo-RNA structure and method for preparing same
KR101392973B1 (ko) 2012-10-15 2014-05-09 (주)바이오니아 ｓｉＲＮＡ 접합체 및 그 제조방법

Also Published As

Publication number Publication date
CA2917299C (en) 2020-07-21
EP3018208B1 (en) 2020-05-27
KR101862349B1 (ko) 2018-05-31
JP2016530875A (ja) 2016-10-06
CN105705638A (zh) 2016-06-22
MX2016000020A (es) 2016-08-18
EP3018208A4 (en) 2017-03-08
US20170152512A1 (en) 2017-06-01
CA2917299A1 (en) 2015-01-08
CN105705638B (zh) 2019-11-26
AU2014284834A1 (en) 2016-02-18
KR20160039607A (ko) 2016-04-11
US10030243B2 (en) 2018-07-24
JP6422961B2 (ja) 2018-11-14
BR112016000160B1 (pt) 2021-06-08
ES2809481T3 (es) 2021-03-04
AU2014284834B2 (en) 2017-06-08
EP3018208A1 (en) 2016-05-11
RU2670164C2 (ru) 2018-10-18
MX378462B (es) 2025-03-10
RU2016103738A (ru) 2017-08-10
WO2015002511A1 (ko) 2015-01-08

Similar Documents

Publication Publication Date Title
PL3018208T3 (pl) Ulepszona struktura oligonukleotydowa typu nanocząstki o wysokiej wydajności i sposób jej wytwarzania
GB2500915B (en) Arrangement and method
GB2520596B (en) Manufacturing method
HUE042269T2 (hu) Nagy hatékonyságú WLAN elõtag struktúra
EP2892056A4 (en) CONDUCTIVE STRUCTURE AND METHOD FOR MANUFACTURING THE SAME
GB201314695D0 (en) Method
IL244560B (en) Method and system for producing nanotubes
ZA201500324B (en) Plantsurface structure and modules and method for forming the same
SG11201603098WA (en) Catalyst for producing higher silane and method for producing higher silane
SG11201509326TA (en) Ship-type structure and method for designing ship-type structure
GB201319878D0 (en) Method, Array and use thereof
SG11201508969QA (en) Method for producing hybrid substrate, and hybrid substrate
PL2956491T3 (pl) Duroplasty, sposoby wytwarzania, zastosowania i kompozycje składników
PL2906827T3 (pl) Pompa i sposób jej wytwarzania
PL3068728T3 (pl) Domieszkowany hydroksy-fosforan miedzi II, sposób jego wytwarzania i stosowania
FI20135243L (fi) Menetelmä nanopartikkelien valmistamiseksi konsentroidussa lietteessä
EP2817395A4 (en) PROCESS FOR THE PRODUCTION OF BIODIESEL
EP2921548A4 (en) PROCESS AND DEVICE FOR MANUFACTURING REFORMING CHARCOAL
EP2942101A4 (en) CATALYTIC REACTOR AND METHOD FOR PRODUCING THE CATALYTIC REACTOR
EP2958353A4 (en) METHOD FOR REALIZING COMMUNICATION IN A WLAN
ZA201405807B (en) Metal colloid solution and method for producing the same
IL242505B (en) A method for producing specific oximes and oximeters
GB2519413B (en) Catalyst and process
EP2878806A4 (en) WINDRAD WING AND METHOD FOR THE PRODUCTION THEREOF
SG11201601264UA (en) Soil-volume reduction method